Further, as a cancer-testis antigen, TSPY protein possesses significant immunogenicity capable of eliciting robust immune and inflammatory responses and thus is a key molecule for development of immunotherapy for HCC, particularly personalized treatments for positive patients. This evidence concerns the gene TSPY1 and hepatocellular carcinoma.